BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 24104864)

  • 1. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.
    Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA
    Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
    Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
    J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
    Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH
    J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM
    Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
    Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is Hepatectomy Justified for BRAF Mutant Colorectal Liver Metastases?: A Multi-institutional Analysis of 1497 Patients.
    Gagnière J; Dupré A; Gholami SS; Pezet D; Boerner T; Gönen M; Kingham TP; Allen PJ; Balachandran VP; De Matteo RP; Drebin JA; Yaeger R; Kemeny NE; Jarnagin WR; D'Angelica MI
    Ann Surg; 2020 Jan; 271(1):147-154. PubMed ID: 29995686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer.
    Huang CJ; Teng HW; Chien CC; Lin JK; Yang SH
    PLoS One; 2014; 8(6):e65117. PubMed ID: 23755178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic and prognostic heterogeneity among RAS/BRAF
    Berg KCG; Brunsell TH; Sveen A; Alagaratnam S; Bjørnslett M; Hektoen M; Brudvik KW; Røsok BI; Bjørnbeth BA; Nesbakken A; Lothe RA
    Mol Oncol; 2021 Apr; 15(4):830-845. PubMed ID: 33325154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Context-dependent interpretation of the prognostic value of BRAF and KRAS mutations in colorectal cancer.
    Popovici V; Budinska E; Bosman FT; Tejpar S; Roth AD; Delorenzi M
    BMC Cancer; 2013 Sep; 13():439. PubMed ID: 24073892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A
    Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases.
    Kemeny NE; Chou JF; Capanu M; Gewirtz AN; Cercek A; Kingham TP; Jarnagin WR; Fong YC; DeMatteo RP; Allen PJ; Shia J; Ang C; Vakiani E; D'Angelica MI
    Cancer; 2014 Dec; 120(24):3965-71. PubMed ID: 25155157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases.
    Løes IM; Immervoll H; Sorbye H; Angelsen JH; Horn A; Knappskog S; Lønning PE
    Int J Cancer; 2016 Aug; 139(3):647-56. PubMed ID: 26991344
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Garcia-Carbonero N; Martinez-Useros J; Li W; Orta A; Perez N; Carames C; Hernandez T; Moreno I; Serrano G; Garcia-Foncillas J
    Cells; 2020 Jan; 9(1):. PubMed ID: 31952366
    [No Abstract]   [Full Text] [Related]  

  • 20. Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer.
    Nakanishi R; Harada J; Tuul M; Zhao Y; Ando K; Saeki H; Oki E; Ohga T; Kitao H; Kakeji Y; Maehara Y
    Int J Clin Oncol; 2013 Dec; 18(6):1042-8. PubMed ID: 23188063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.